Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associations of various healthy dietary patterns with biological age acceleration and the mediating role of gut microbiota: results from the China Multi-Ethnic Cohort study.
Zhang H, Zuo H, Xiang Y, Cai J, Zhang N, Yang F, Huang S, Zhang Y, Chen H, Li S, Yang T, Mi F, Chen L, Han M, Li J, Xiao X, Zhao X. Zhang H, et al. Among authors: mi f. Br J Nutr. 2024 Nov 4:1-31. doi: 10.1017/S0007114524002733. Online ahead of print. Br J Nutr. 2024. PMID: 39494614
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M. Song Y, et al. Among authors: mi f. BMC Med. 2024 Oct 15;22(1):465. doi: 10.1186/s12916-024-03694-4. BMC Med. 2024. PMID: 39407203 Free PMC article. No abstract available.
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M. Song Y, et al. Among authors: mi f. BMC Med. 2024 Sep 19;22(1):401. doi: 10.1186/s12916-024-03633-3. BMC Med. 2024. PMID: 39300460 Free PMC article. Clinical Trial.
252 results